Key facts
- It has raised $30.4M; the latest was Later Stage VC in Jan 2026.
- Notable investors include CICC Capital, Shanghai Alliance Investment, Alpha Asset Management China, Cenova Capital, Jiangsu Winfast Investment — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Youlin Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Youlin Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Youlin Pharmaceutical
Operator of a contract research organization intended for pharmaceutical companies, biotechnology firms, and clinical research institutions. The company provides clinical strategy, program design, statistics and data management, clinical operations, IRC, biological analysis, and embedded SMO services, thereby enabling clients to coordinate strategy, regulatory pathways, data operations, trial execution, and safety oversight through a unified CRO platform.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2017
- Employees
- 500
- Website
- unionclin.com/
- Ownership
- Privately Held (backing)
Youlin Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Youlin Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Youlin Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.